The incretin hormone glucagon-like peptide 1 (GLP-1) is a key component of the signaling
mechanisms promoting glucose homeostasis. Clinical and experimental studies …

Glucagon-like peptide-1 (GLP-1), is a hormone secreted by small intestine. Consumption of
food or glucose stimulates synthesis and secretion of GLP-1 in the bloodstream, which in …

Aims New drugs for type 2 diabetes need to demonstrate their cardiovascular safety, due
regulatory requirements from the Food and Drug Administration. For this reason, glucagon …

Glucagon-like peptide-1 (GLP-1)-based therapy of type 2 diabetes is executed either by GLP-
1 receptor agonists, which stimulate the GLP-1 receptors, or by dipeptidyl peptidase-4 (DPP …

Objective. Data from randomized clinical trials with metabolic outcomes can be used to
address concerns about potential issues of cardiovascular safety for newer drugs for type 2 …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to treat patients
with type 2 diabetes since 2005 and have become popular because of the efficacy and …

The incretin system is an area of great interest for the development of new therapies for the
management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting …

The active incretin hormone glucagon-like peptide-1 (7-36) amide (GLP-1) is a 30-amino
acid peptide that exerts glucoregulatory and insulinotropic actions by functioning as an …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

AIM: Glucagon-like peptide-1 (GLP-1) belongs to the incretin hormone family: in the
presence of elevated blood glucose, it stimulates insulin secretion and inhibits glucagon …